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Objectives. We sought to compare the effects of captopril plus 
isosorbide dinitrate versus monotherapy on infarct collagen con- 
tent and left ventricular remodeling and function during healing 
after myocardial infarction. 
Background. Captopril or isosorbide dinitrate monotherapy 
can limit postinfarction dilation. Whether captopril inhibits in- 
farct collagen content, or whether captopril plus isosorbide dini- 
trate might be more beneficial, is not known. 
Methods. In vivo remodeling variables and function (echocar- 
diography), hemodynamic variables, postmortem topography 
(planimetry) and collagen content (hydroxyproline) were mea- 
sured in 48 chronically instrumented ogs that were randomized 
2 days after left anterior descending coronary artery ligation to 6 
weeks of therapy with captopril, isosorbide dinitrate, captopril 
plus isosorbide dinitrate or placebo. 
Results. Compared with placebo, the three active therapies 
decreased blood pressure and left atrial pressure; limited infarct 
expansion, infarct thinning, noninfarct wall stretching and thick- 
ening; limited left ventricular dilation and increase in left ventric- 
ular mass; and decreased regional bulging, aneurysm frequency 
and left ventricular dysfunction. However, the decrease in asyn- 
ergy and increase in volume ejection fraction were less with 
captopril or captopril plus isosorbide dinitrate than with isosor- 
bide dinitrate. Infarct thinning and bulging at 6 weeks was also 
less with isosorbide dinitrate than with captopril. Although initial 
left ventricular asynergy, final scar sizes and noninfarct collagen 
content at 6 weeks were similar among the groups, collagen in the 
center of the infarct scar was less with captopril or captopril plus 
isosorbide dinitrate than with placebo or isosorbide dinitrate. 
Conclusions. Monotherapy with captopril or isosorbide dini- 
trate, or their combination, improved all remodeling variables, 
but isosorbide dinitrate improved function more than captopril or 
captopril plus isosorbide dinitrate. Inhibition of infarct collagen 
content by captopril suggests that benefits with captopril repre- 
sent a balance between positive and negative effects, and its 
combination with isosorbide dinitrate might be advantageous. 
(J Am Coil Cardiol 1995;25:1089-96) 
Structural remodeling of infarct and noninfarct regions during 
healing after myocardial infarction (1) contributes to left 
ventricular dilation and dysfunction and decreased survival 
(2,3). Prolonged left ventricular unloading after infarction, by 
reducing wall stress, can limit remodeling, prevent chamber 
dilation and preserve function (4,5). These results were 
achieved with the angiotensin-converting e zyme inhibitor 
captopril n rats (6), dogs (7,8) and humans (9) and translated 
into survival benefit in rats (10) and humans (11). However, 
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recent reports indicate that captopril (12), other angiotensin- 
converting enzyme inhibitors (13) and angiotensin II receptor 
blockade (14) decrease noninfarct collagen content. Long- 
term unloading with nitrate therapy, in dose regimens to 
minimize tolerance, also limits remodeling and improves func- 
tion (5) and decreases ventricular distensibility and rupture 
threshold (15) in dogs. However, nitrate therapy does not 
decrease infarct or noninfarct collagen content at 1 or 6 weeks 
(5,15); rather, it increases infarct collagen at 1 week (16). 
Because captopril can potentially decrease infarct collagen 
content (12,17,18) and donate sulfhydryl radicals (19) that are 
depleted during long-term nitrate therapy (20), and both 
nitrates (21,22) and angiotensin-converting e zyme inhibitors 
(23,24) exert local vascular and tissue effects that might show 
synergism, the combination of captopril and nitrate might 
prove more beneficial than monotherapy. 
The present study therefore compared the effects of com- 
bined therapy with captopril and isosorbide dinitrate versus 
monotherapy onremodeling and function as well as infarct and 
noninfarct collagen content during postinfarct healing in a well 
defined og model (5,7). 
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Methods  
Experimental preparation. The experiments were ap- 
proved by the institutional animal welfare committee and 
conformed to the "Position of the American Heart Association 
on Research Animal Use" adopted by the Association in 
November 1984. Sixty healthy mongrel dogs (16 to 29 kg) of 
either gender were chronically instrumented through a left 
lateral thoracotomy under general anesthesia (sodium pento- 
barbital, 30 mg/kg body weight intravenously), as previously 
described (5,7). Polyethylene catheters were inserted in the 
external jugular vein, internal carotid artery and left atrium, 
filled with heparinized saline solution, and their ends exterior- 
ized behind the neck. The mid-left anterior descending coro- 
nary artery was ligated with silk. Pairs of metal beads were 
sutured on anterior, lateral and posterior surfaces of the left 
ventricular epicardium in the short-axis plane at the mid- 
occluded bed for consistent echocardiographic imaging. After 
closure of the pericardium and chest, penicillin (1 million U) 
and streptomycin (1g) were given intramuscularly. 
Protocol. Two days after ligation, 52 healthy survivors were 
randomized tofour treatment groups (13 each) using a facto- 
rial design: placebo twice a day; captopril 50 mg twice a day; 
isosorbide dinitrate 30 mg twice a day on an eccentric 8 AM, 
4 PM schedule to allow a washout phase; and captopril twice a 
day plus isosorbide dinitrate twice a day. The dogs were given 
free access to fluids, and no attempt was made to treat heart 
failure. At 6 weeks, the 48 surviving dogs were anesthetized, 
and the hearts were arrested in diastole with an overdose of 
intravenous potassium chloride and excised, washed in normal 
saline solution and weighed. 
In vivo measurements during healing. As described previ- 
ously (5,7), two-dimensional echocardiograms (Toshiba SSH- 
65A; 3.5-MHz transducer), electrocardiograms (Gould re- 
corder) and hemodynamic variables (Statham P23Db for left 
atrial and arterial pressures) were recorded at eight intervals in 
conscious dogs standing in a sling for support as follows: before 
therapy at 2 days, weekly during therapy and again after 
therapy and before they were killed. Recordings were made 3 
to 4 h after the first daily doses. Echocardiograms were also 
obtained before and after surgery. Standard parasternal long- 
and short-axis views of the mitral, chordal, low and mid- 
papillary and apical levels and apical four- and two-chamber 
views were used. 
Analysis of echocardiograms. As described previously 
(5,7), coded echocardiograms were analyzed in double-blind 
manner on video playback (0.5-in. tapes) by two independent 
observers, and differences were resolved by consensus. Briefly, 
endocardial nd epicardial outlines of left ventricular images at 
end-diastole and end-systole were traced with a light pen 
(Diasonics CardioRevue Center) and copied on plastic over- 
lays. Anatomic landmarks uch as papillary muscles were 
indicated on the tracings. Asynergy, defined as akinesia (no 
systolic inward motion and thickening) or dyskinesia (systolic 
outward motion and thinning), or both, was marked on each 
endocardial diastolic outline. The circumferential extent of 
asynergy on each short-axis outline was then digitized 
(Hewlett-Packard models 9878A and 9835A) and used to 
compute total endocardial surface area asynergy by a three- 
dimensional reconstruction algorithm. Outlines from five 
short-axis and two long-axis views were used to compute 
volumes by means of a modified Simpson rule algorithm. 
Global ejection fraction was calculated as end-diastolic volume 
minus end-systolic volume divided by end-diastolic volume. 
Interobserver ror was <5% in marking asynergy, segment 
length, wall thickness and areas of outlines, in agreement with 
previous tudies (5,7). Topographic measurements were made 
on end-diastolic outlines of papillary short-axis images, and 
expansion index (ratio of the lengths of asynergy-containing 
and nonasynergy-containing segments), thinning ratio (ratio of 
average thicknesses of asynergic and nonasynergic zones) and 
regional area ejection fraction (end-diastolic area minus end- 
systolic area divided by end-diastolic area) were computed. 
Regional bulging of the asynergic zone was characterized byits 
area and depth, as described previously (5,7,8). Left ventricular 
aneurysm was defined as a bulging in diastole and further 
bulging in systole. Left ventricular mass was calculated from 
the volume of myocardiurn (difference in volumes of epicardial 
and endocardial shells at end-diastole) multiplied by an as- 
sumed specific gravity of 1.05 g/ml. 
Postmortem measurement of scar size, geometry and col- 
lagen content. As described previously (5,7), the risk region 
was measured on postmortem coronary arteriogram8 recorded 
on whole-heart and transverse section (1 to 1.5 cm thick) 
radiographs. Outlines of weighed left ventricular rings, risk 
regions and infarct scars were made on plastic overlays and 
subjected to computerized planimetry (Hewlett-Packard 
9835A computer and 9874A digitizer interfaced with a VAX 
750 computer) for infarct size and topography, including 
"thinning" ratio (ratio of average thickness of infarcted wall to 
average thickness of the normal wall) and "expansion" index 
(ratio of endocardial lengths of infarct-containing to noninfarct- 
containing segments demarcated by papillary muscles), and 
short-axis topographic maps were made for each group (5,7). 
Contours of the left ventricular epicardium and endocardium 
from whole-heart adiographs were digitized to measure the 
area and depth of the apical bulge and construct topographic 
long-axis maps for each group (5,7). Histopathologic studies 
for extent of infarction and collagen content (1) were per- 
formed using a 5-ram slice from the middle of the infarct zone 
and triplicate 5-p~m thick sections that were stained with 
hematoxylin-eosin, Mallory's stain or Masson's trichrome, re- 
spectively. Myocardial hydroxyproline (mg/g dry tissue weight), 
a marker for collagen, was measured in 100 to 200 mg samples 
from center and border regions of the infarct scar, after 
excising visually normal tissue on gross examination, and the 
noninfarct center (1,16). 
Statistics. Data were analyzed in blinded manner. The 
statistical tests used were 1) analysis of variance (univariate) 
for differences within and between separate or combined 
groups; 2) repeated measures analysis of variance with orthog- 
onal contrast for comparing serial data within groups and a 
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multigroup repeated measures design for overall differences 
between groups; 3) multiple comparisons analysis of variance 
and the Student Newman-Keuls test for the significance be- 
tween placebo and separate or combined therapy groups; and 
4) chi-square and Fisher exact tests for the significance of 
difference in event frequency among groups. The main pre- 
defined comparisons were captopril versus placebo, isosorbide 
dinitrate versus placebo and captopril plus isosorbide dinitrate 
versus placebo. Results are presented as mean value + SD 
unless otherwise stated. Statistical significance was set at p < 
0.05 (two-tailed). 
Resu l ts  
Study groups. Of the 52 dogs that were randomized, one 
from each group died. Data from the 48 survivors that were 
killed at 6 weeks (12 in each group) form the basis of this 
report. 
Hemodynamic hanges. The 2-day pretreatment values 
were similar among the groups, with average values for all 48 
dogs as follows: heart rate 138 + 26 beats/rain, mean arterial 
pressure 112 _+ 15 mm Hg and left atrial pressure 15 _+ 
4 mm Hg. Baseline variables measured 3 to 4 h after treatment 
showed no change with placebo but significant decreases (p < 
0.005) in atrial (11%) and arterial (9%) pressure with the 
active drugs. In Figure 1 (points in Fig. 1 to 6 are offset around 
time lines for clarity), most atrial and arterial pressures 
decreased further over the 6 weeks. Compared with placebo at 
6 weeks, the combined active therapy groups howed a greater 
decrease in atrial pressure (-33% vs. -15%, p < 0.05) and 
arterial pressure ( - l  1% vs. + 3%, p < 0.025) but no significant 
decrease in heart rate (-28% vs. -41%, p < 0.2). The 
decrease in atrial pressure over the 6 weeks was more pro- 
nounced with isosorbide dinitrate (Fig. 1). Mild increases (p -< 
0.05) in atrial and arterial pressures were seen after drug 
withdrawal at 6 weeks (Fig. 1). 
Changes in infarct and noninfarct wall stretch. For all 48 
dogs, mean anterior and posterior segment lengths were 8.7 _+ 
1.4 and 4.2 +_ 0.2 era, respectively, preocclusion and 11.2 +_ 1.5 
and 4.6 _+ 0.8 cm, respectively, at the 2-day baseline, indicating 
predominant elongation of the infarct segment by day 2. There 
was no difference in these baseline variables among groups. 
However, all active therapies prevented elongation of infarct- 
and noninfarct-containing se ments and decreased the expan- 
sion index over the 6 weeks compared with placebo (Fig. 2). 
Changes in infarct and noninfarct wall thickness. For all 
48 dogs, the mean anterior and posterior wall thicknesses were 
0.95 versus 0.95 cm preocclusion and 0.65 + 0.11 versus 0.97 _+ 
0.11 cm (p < 0.001) at the 2-day baseline, indicating infarct 
wall thinning by day 2. These baseline thicknesses did not differ 
among the groups. However, all active therapies attenuated 
the infarct wall thinning and noninfarct wall thickening seen 
over the 6 weeks with placebo (Fig. 3). In addition, the change 
in infarct wall thickness at 6 weeks was slightly higher for 
isosorbide dinitrate than captopril (+ 12% vs. +4%, p < 0.05) 
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Figure 1. Percent changes inheart rate (top), arterial pressure (mid- 
dle) and left atrial pressure (bottom). CL = captopril; D = day; 
ISDN = isosorbide dinitrate; PDW = after drug withdrawal; PL = 
placebo; W = week. *p -< 0.05, placebo versus active therapy, tp -< 
0.05, least significant difference, isosorbide dinitrate or captopril plus 
isosorbide dinitrate versus placebo. Sp < 0.05, isosorbide dinitrate 
versus captopril. Data shown are mean value _+ SEM. 
vs. +4%, p < 0.05), indicating less thinning with isosorbide 
dinitrate or captopril plus isosorbide dinitrate than with cap- 
topril. 
Changes in regional bulging and aneurysm frequency. All 
active therapies decreased diastolic bulging of asynergic zones 
compared with placebo. Thus, the decrease inarea of the bulge 
was greater with active therapies than placebo (-82% vs. 
-5%, p < 0.001). The frequency of ventricular aneurysm was 
lower with captopril (3 of 12 vs. 12 of 12, chi-square 11.38, p < 
0.001), isosorbide dinitrate (0 of 12 vs. 12 of 12, chi-square 
20.17, p < 0.001) and captopril plus isosorbide dinitrate (0 of 
12 vs. 12 of 12, chi-square 20.17, p < 0.001) than placebo but 
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Figure 2. In vivo percent changes in anterior (top) and posterior 
(middle) segment lengths and infarct expansion (bottom). *p < 0.001, 
*p < 0.01, :~p < 0.05, placebo versus active therapy; p values between 
plots = placebo versus active therapy groups combined. Abbreviations 
as in Figure 1. Data shown are mean value _+ SEM. 
was not different between captopril and isosorbide dinitrate 
groups (3 of 12 vs. 0 of 12, p > 0.15). 
Changes in ventricular dilation. There was no difference in 
baseline diastolic and systolic volumes or diastolic endocardial 
surface area among the groups at 2 days; mean values for the 
48 dogs were 80 2 23 and 45 2 17 ml and 85 2 18 cm 2, 
respectively. However, all active therapies limited the progres- 
sive increase in diastolic and systolic volumes and diastolic 
surface area found with placebo between 2 days and 6 weeks 
(Fig. 4). Changes in diastolic and systolic areas (papillary level) 
were similar to changes in volumes. 
Changes in left ventricular mass. Baseline mass at 2 days 
was similar among the groups and averaged 90 2 10 g for all 48 
dogs. However, all active therapies limited the increase in mass 
found with placebo between 2 days and 6 weeks, and the 
magnitude of the effect was similar among therapy groups (Fig. 
5). 
Changes in regional and global left ventricular function. 
There was no difference in baseline circumferential synergy, 
endocardial surface area of asynergy, area ejection fraction or 
volume ejection fraction among the groups at 2 days, and the 
values for all 48 dogs were 29 _+ 8%, 22 _+ 10%, 31 _+ 8% and 
45 _+ 7%, respectively. However, all active therapies decreased 
regional dysfunction and improved global systolic function 
between 2 days and 6 weeks compared with placebo (Fig. 6). 
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Figure 3. In vivo percent changes in anterior (top) and posterior 
(middle) wall thicknesses and infarct thinning (bottom). *p < 0.01, 
,~p < 0.05, :~p < 0.01, placebo versus active therapy groups; p values 
between plots = placebo versus active therapy groups combined. 
Abbreviations as in Figure 1. Data shown are mean value - SEM. 
and global systolic function with isosorbide dinitrate than 
captopril or their combination (Fig. 6). 
Postmortem scar size. There were no statistically signifi- 
cant differences in the mass of the scar, left ventricle or risk 
region in the groups at 6 weeks (Table l). No differences in 
standard histologic studies of scar tissue were detected among 
the groups. 
Postmortem topography. Average short-axis maps at the 
low papillary level showed less cavity area, infarct wall thinning 
and noninfarct wall thickness with active therapies than pla- 
cebo (Table 2). However, the infarct scar wall was slightly 
thicker with isosorbide dinitrate than captopril and captopril 
plus isosorbide dinitrate. Despite equal infarct scar areas 
among therapy groups, the transmural extent was less with 
captopril, suggesting a flattening of the scar. Average long-axis 
maps showed less apical bulging, smaller cavity areas and less 
apical scar thinning with active therapies than placebo (Table 
2). The bulge and scar thinning were slightly less with isosor- 
bide dinitrate than captopril and captopril plus ISDN. 
Effect on regional collagen. Noninfarct collagen content 
was similar among the groups, but infarct collagen content 
differed considerably (Fig. 7). As noted previously (5,7,8), 
collagen content was greater in the center (p < 0.001) and 
border (p < 0.05) of the infarct than in the noninfarct region 
for each group. However, collagen content in the infarct center 
JACC Vol. 25, No. 5 JUGDUTF ET AL. 1093 
April 1995:1089-96 CAPTOPRIL AND NITRATE ON REMODELING 
41, 20 
-2 









t t t t t t 
- - / - : CL+ISDN 
I ~ ~ ~ I i  ISDN 
20-  $ 
10 - ~ I I PL 
\ 
O- ~ CL+ISDN 
- lO - ISDN 
CL 
-20 - 
I I I I I r r 
2D lW 2W 3W 4W 5W 6W 
Figure 4. In vivo percent changes in end-diastolic (top) and end- 
systolic (middle) volumes and surface area (bottom). *t~:p < 0.01, 
placebo versus active therapy; pvalues between plots = placebo versus 
active therapy groups combined. Abbreviations as in Figure 1. Data 
shown are mean value _+ SEM. 
and border regions for isosorbide dinitrate did not differ from 
that for placebo but were significantly less for captopril and 
captopril plus isosorbide dinitrate (Fig. 7). The increase in 
collagen in the infarct center with placebo was similar to that 
with isosorbide dinitrate (994% vs. 1,056%, p > 0.51) but 
significantly greater than that with captopril (994 _+ 504% vs. 
507 _+ 282%, p < 0.01) or captopril plus isosorbide dinitrate 
(994 _+ 504% vs. 388 _ 289%, p < 0.005). The increase in 
Figure 5. In vivo percent changes in left ventricular (LV) mass. *p < 
0.001, placebo versus active therapy; p value between plots = placebo 
versus active therapy groups combined. Abbreviations as in Figure 1. 














. .;. -; 
1 
~ ~  ISDN 
J ~ captopri l  
D 
I I I [ I I I 




-40  - 
-60 
* $ $ $ IlK 
!-PL 
~"~.~ p<0.01 / 
~ J : ~ E ~ m ~ C L  ~ p<O.01 
~ .  "i .U_ ~"CL+IS IDN 
I ~ p<0.05 
~ ~ ISDN "J 
80-  
6o-  1- / ~  
! 1 40- T T ~ p<o.ol I 
CL ~J  p<O.O 1 
20-  ~ . ~ ~ C L +  SDN , 
/ ~ j~  p<O.O5 / 
o-  1 
t t t -20 - 
I I I I I I I 
2D lW 2W 3W 4W 5W 6W 
Figure 6. In vivo percent changes in regional ventricular dysfunction 
(top) and volume ejection fraction (bottom). *tp < 0.01, placebo 
versus active therapy groups; p values at right = placebo versus 
isosorbide dinitrate, and placebo r isosorbide dinitrate versus capto- 
pril and captopril plus isosorbide dinitrate. Abbreviations as in Figure 
1. Data shown are mean value _+ SEM. 
collagen in the infarct center was also greater with isosorbide 
dinitrate than captopril (1056 _+ 600% vs. 507 _+ 282%, p < 
0.025) or captopril plus isosorbide dinitrate (1056 _+ 600% vs. 
388 _+ 289%, p < 0.005). The trend was similar for the scar 
border region. 
Discuss ion  
There are three new findings in this study: 1) Combination 
therapy with captopril plus isosorbide dinitrate and mono- 
therapy with captopril or isosorbide dinitrate had a similar 
beneficial effect on several in vivo variables of remodeling 
between 2 days and 6 weeks after canine anterior myocardial 
infarction. Thus, compared with placebo, all active therapies 
limited infarct segment stretching, infarct wall thinning, en- 
largement of left ventricular diastolic and systolic volumes, 
increase in noninfarct segment length and wall thickness, 
increase in end-diastolic endocardial surface area, increase in 
left ventricular mass, bulging of the infarct zone and aneurysm 
formation. 
2) The active therapies improved regional and global 
systolic function compared with placebo, but the decrease in 
asynergy and improvement in ejection fraction were greater 
with isosorbide dinitrate than with captopril or captopril plus 
isosorbide dinitrate. 
3) Collagen content in the center of the infarct scar at 6 
weeks was lower with captopril or captopril plus isosorbide 
dinitrate compared with isosorbide dinitrate or placebo. This 
effect was associated with slightly greater preservation of 
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Table 1. Infarct Scar Size (mean +_ SD) in the Four Study Groups 
Placebo Captopril ISDN Captopril + ISDN 
(n = 12) (n = 12) (n = 12) (n = 12) p Value 
Infarct scar mass (g) 6.0 ± 2.1 4.0 ± 3.6 5.9 _+ 4.5 4.8 ± 2.0 0.76 
Risk region mass (g) 13.3 + 4.1 14.8 + 5.6 15.8 + 8.2 11.4 ± 4.2 0.56 
LV mass (g) 76.2 ± 16.l 80.8 ± 8.5 79.3 ± 14.6 80.8 ± 14.0 1.64 
Infarct scar/risk (%) 46.4 + 13.9 28.7 ± 22.9 35.3 +_ 19.6 45.1 ± 18.8 0.17 
Risk/LV mass (%) 17.7 _+ 5.3 18.6 _+ 7.8 20.0 ± 11.1 14.4 ± 5.2 0.69 
Infarct/LV mass (%) 7.8 _+ 1.9 5.1 _+ 4.8 7.4 ± 5.8 6.1 ± 2.5 0.71 
ISDN = isosorbide dinitrate; LV = left ventricular. 
infarct wall thickness and less bulging at 6 weeks with isosor- 
bide dinitrate or captopril plus isosorbide dinitrate than with 
captopril. 
Mechanisms. Several factors might have contributed to the 
therapeutic benefit: 1) Vasodilation, left ventricular unloading 
and reduced diastolic stress probably played a major role 
because arterial and especially left atrial pressures measured 3 
to 4 h after drug therapy were mostly lower, left ventricular 
chamber size was smaller, and regional bulging was less with 
active therapy than placebo. Current evidence suggests that 
isosorbide dinitrate produces vasodilation by donating nitric 
oxide (25), stimulating uanylate cyclase and increasing cyclic 
guanosine monophosphate, whereas angiotensin-converting 
enzyme inhibitors such as captopril mediate vasodilation by 
decreasing bradykinin breakdown and increasing bradykinin, 
which releases nitric oxide (25) and prostacyclin (26). In- 
creased nutrient flow, through dilation of coronary arteries and 
collateral vessels or reduced endocardial compression from 
diastolic unloading (4), might have provided further benefit. 
Because venodilation leads to decreased chamber size and 
diastolic wall stress (Laplace's law), which in turn decreases 
wall stretch, decreases gene expression of contractile and 
noncontractile proteins and prevents hypertrophy (23,27), this 
mechanism ight partly explain the decrease in left ventricular 
mass observed with active therapy. 
2) Tissue effects may be involved. Thus, the decrease in 
ventricular mass with nitrates (5,28) might in part be mediated 
by an antimyocyte hypertrophic effect of nitric oxide, similar to 
its known inhibition of mitogenesis and smooth muscle prolif- 
eration (21). The antibypertrophic effect of captopril appears 
to be mediated by inhibition of circulating angiotensin II as 
well as tissue angiotensin-converting enzyme inhibitors and 
intramyocardial conversion of angiotensin I to angiotensin-II, 
decreased local angiotensin II (24), angiotensin II type I 
receptor blockade (14) and decreased activity of both myocyte 
and fibroblast growth factors (13,18,29,30). 
3) Effects on the supporting matrix might have contributed 
in limiting remodeling and preserving function. Because in- 
creased wall stress and decreased flow damage the matrix 
(31,32), therapy-induced decrease in diastolic wall stress and 
increase in nutrient flow might preserve matrix integrity. It is 
also possible that mechanical coupling between collagen fibrils 
and live myocytes at the infarct scar borders (33) was improved 
by the therapies, especially isosorbide dinitrate, and contrib- 
Table 2. Postmortem Measurements (mean + SD) on Average Topographic Maps 
Placebo Captopril ISDN Captopril + ISDN 
(n = 12) (n - 12) (n = 12) (n = 12) 
Short-axis map (low papillary) 
Angular extent of infarct (0 ~) 107 _- 4 88 _+ 13"t 84 _+ 4"~: 121 ± 6* 
Infarct wall thickness (ram) 8 - 1 8 + I t  10 ± 1"~§ 9 + 1' 
Noninfarct wall thickness (mm) 15 _~ 1 13 _+ 1' 13 ± 1' 13 ± 1" 
Area of infarct scar (cm 2) 5.0 _+ 0.8 3.1 ± 0.7*t 3.4 + 0.9* 3.7 ± 0.3* 
Transmural extent of scar (%) 62 + 7 48 +_ 11" 60 + 7~§ 64 ± 6 
LV cavity area (cm 2) 4.7 +_ 0.9 3.4 + 0.9*t 2.6 + 0.7*§ 2.8 _+ 0.2* 
Long-axis map (radiographs) 
Area of apical bulge (cm 2) 
Endocardial 1.2 _+ 1.1 0.2 + 0.1" 0.2 + 0.2* 0.1 ± 0.1' 
Epicardial 0.8 - 0.3 0.1 ± 0.1' 0.1 ± 0.1' 0.1 _+ 0.1' 
Depth of apical bulge (ram) 
Endocardial 6.6 - 2.8 3.3 ± 1.2" 2.2 ± 1.5"§ 2.8 +_ 1.9" 
Epicardial 3.4 - 1.6 0.8 ± 0.8* 0.7 ± 0.6* 0.8 ± 0.9* 
Area of LV cavity (cm 2) 13.7 _- 3.6 11.3 ± 2.1't 11.8 ± 2.0*$ 9.4 ± 1.2" 
Apical wall thickness (ram) 4.6 _~ 1.3 6.8 ± 1.5't 8.0 ± 2.1'§ 8.0 -+ 2.4* 
*p -< 0.05, each active therapy versus placebo, tp _< 0.05, captopril versus captopril plus isosorbide dinitrate (ISDN). 
~:p -< 0.05, isosorbide dinitrate versus captopril plus isosorbide dinitrate. §p -< 0.05, isosorbide dinitrate versus captopril. 
LV - left ventricular. 
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Figure 7. Bar graphs of myocardial hydroxyproline content in infarct 
and noninfarct regions. ISDN = isosorbide dinitrate. Data shown are 
mean value _+ SD; p values indicate the difference b tween groups by 
analysis of variance. 
uted to improved mechanical function. Whether the greater 
improvement in function with isosorbide dinitrate might have 
been due to the greater decrease in left atrial pressure (an 
index of preload), resulting in more nutrient flow and more 
preservation of the matrix and mechanical function, is not 
clear. The finding that hemodynamic effects of isosorbide 
dinitrate were not sustained over 24 h with the eccentric dosing 
suggests hat intermittent unloading can influence remodeling 
and that other as yet poorly defined mechanisms might be 
operational. 
Infarct collagen. To our knowledge, a decrease in infarct 
collagen with long-term angiotensin-converting e zyme inhibi- 
tion during infarct healing, as seen with captopril in our dog 
infarction model, has not been previously reported. The reason 
why captopril decreased infarct but not noninfarct collagen 
content might be because angiotensin-converting e zyme inhi- 
bition is more likely to influence active collagen deposition. In 
the rat model, where infarctions are large, involve the entire 
free wall and only spare the septum, and there is marked left 
ventricular dilation, hypertrophy and increased collagen in the 
noninfarcted septum, early captopril therapy during infarct 
healing inhibits DNA synthesis, fibroblast proliferation and 
collagen deposition in noninfarct regions (12). This effect on 
noninfarct collagen content is also seen when the angiotensin- 
converting enzyme inhibitor perindopril (13) or the angiotensin II 
type I receptor blocking agent losartan (14) is given during and 
after healing but is not seen when captopril is given after 
healing (26). Unlike rat infarcts, the anterior infarcts in our 
dog model were small, mainly anteroapical nd caused mild 
chamber dilation, and noninfarct collagen content did not 
increase on standard histologic or biochemical ssay. However, 
captopril decreased collagen content in the infarct scar and 
altered scar topography, causing flattening, less transmural 
extent but similar area compared with other therapies. The 
decrease in collagen synthesis by captopril was probably me- 
diated by inhibition of local effects of angiotensin II and 
decreased activity of fibroblast growth factor and transforming 
growth factor-beta1, which are known to modulate xtracellu- 
lar matrix and stimulate collagen synthesis (34,35). Whether 
altered collagenase activity played a role is not known. It is 
possible that a decrease in infarct collagen content might allow 
more remodeling under the effect of mechanical forces during 
healing in vivo (3), especially in the setting of large transmural 
infarctions. Although isosorbide dinitrate did not decrease 
infarct collagen content, it did not prevent he decrease in 
infarct collagen caused by captopril. However, the preserved 
infarct collagen with isosorbide dinitrate might have contrib- 
uted to the striking improvement in regional and global 
ventricular function. 
Study limitations. The infarct scars in our model were 
small as a result of shrinkage, which decreases infarcts of 
-20% of the left ventricle at day 1 to -10% at 6 weeks (1,5). 
However, they were mostly subendocardial sothat remodeling 
(36) and matrix disruption in the risk zone (37) were less 
severe than that seen with transmural infarctions. Because we 
did not measure the mechanical strength of the infarct scars 
(5), whether an infarct scar with less collagen might be weaker 
remains unanswered. Our failure to demonstrate superiority of 
combined therapy might in part be due to the small infarct 
scars and small sample sizes. 
Clinical implications. The aim of therapy to limit left 
ventricular emodeling during infarct healing should be to 
decrease deformation forces and preserve shape, prevent 
excessive dilation, prevent excessive infarct stretching and 
thinning, promote healing and preserve nutrient flow, protect 
the supporting collagen matrix and possibly limit hypertrophy 
and further necrosis (3). The final outcome depends on the 
balance of effects. In subendocardial infarctions, an epicardial 
rim of normal myocardium and collagen matrix appears to act 
as a scaffold that resists bulging, so that decreased infarct 
collagen and matrix disruption might not impact as signifi- 
cantly on outcome as large transmural infarctions. 
Conclusions. In the present study, prolonged therapy with 
captopril or isosorbide dinitrate, or both, during healing of 
relatively small anterior myocardial infarction limited remod- 
eling and improved systolic function in vivo and improved 
topography at 6 weeks despite a decrease in infarct collagen 
content with captopril. Although captopril-induced decrease in 
infarct collagen might explain the lesser improvement in 
function compared with isosorbide dinitrate, the effect did not 
have a significant negative impact on in vivo remodeling 
variables. The overall results suggest hat the benefits of 
angiotensin-converting e zyme inhibition represent a balance 
of positive and negative ffects. Whether combination therapy 
with a nitrate might be advantageous in the setting of large 
anterior infarction eeds further study. 
We are grateful to Vijayan Menon for computing and statistics, Anil Bhambhani, 
Ruwan Liyanage and Michael Joljart for data processing and Catherine Graham 
for typing. 
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